<DOC>
	<DOCNO>NCT01760655</DOCNO>
	<brief_summary>This clinical trial study reduced-intensity conditioning donor stem cell transplant treat patient high-risk hematologic malignancy . Giving low-doses chemotherapy total-body irradiation donor stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Giving infusion donor 's T cell ( donor lymphocyte infusion ) transplant may help increase effect .</brief_summary>
	<brief_title>Reduced-Intensity Conditioning Before Donor Stem Cell Transplant Treating Patients With High-Risk Hematologic Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : 1 . To compare rate disease-free survival ( DFS ) 1 year post hematopoietic stem cell transplant ( HSCT ) patient undergo HSCT treat successor Thomas Jefferson University ( TJU ) 2 Step reduce intensity conditioning ( RIC ) haploidentical regimen compare initial 2 Step RIC regimen . SECONDARY OBJECTIVES : 1 . To assess 100 day regimen-related mortality ( RRM ) patient undergo HSCT treatment protocol . 2 . To determine incidence severity graft-versus-host disease ( GVHD ) patient undergo treatment regimen . 3 . To evaluate engraftment rate lymphoid reconstitution patient treat trial . 4 . To assess overall survival 1 3 year past HSCT patient treat trial . OUTLINE : REDUCED INTENSITY CONDITIONING : Patients receive fludarabine phosphate intravenously ( IV ) 60 minute day -15 -12 , thiotepa IV 2 hour day -15 -13 , donor lymphocyte infusion ( DLI ) day -6 , cyclophosphamide IV 2 hour day -3 -2 . Patients also undergo total-body irradiation ( TBI ) day -10 . TRANSPLANT : Patients undergo allogeneic peripheral blood stem cell transplant ( PBSCT ) day 0 . GVHD PROPHYLAXIS : Patients receive tacrolimus IV day -1 42 follow taper mycophenolate mofetil IV twice daily ( BID ) day -1 28 . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Any patient highrisk hematologic oncologic diagnosis allogeneic HSCT think beneficial , frontline therapy already apply . High risk define : 1 . Acute myeloid leukemia high risk feature define : Age great equal 60 Secondary AML ( prior therapy hematologic malignancy ) Normal cytogenetics FLT3/ITD positive Any relapse primary refractory disease Greater 3 cytogenetic abnormality one follow cytogenetic abnormality : 5/del ( 5q ) , 7/del ( 7q ) , Abn ( 9q ) , ( 11q ) , ( 3q ) , ( 21q ) , ( 17p ) , ( 6 ; 9 ) , ( 6 ; 11 ) , ( 11 ; 19 ) , +8 , del ( 12p ) , inv ( 3 ) , ( 10 ; 11 ) ,17 , 11q 23 Any single autosomal monosomy 2 . Acute lymphoid leukemia 1st 2nd morphological remission . ALL morphological evidence disease eligible . 3 . Myelodysplasia ( MDS ) refractory anemia ( RA ) , refractory anemia rare sideroblast ( RARS ) , isolate 5q syndrome subtypes . 4 . Hodgkin 's NonHodgkin 's lymphoma 2nd great remission persistent disease . 5 . Myeloma evidence persistent disease frontline therapy . 6 . Chronic myeloid leukemia ( CML ) resistant signal transducer inhibitor ( STI ) therapy 7 . Myelofibrosis CMML 8 . Essential Thrombocytopenia Polycythemia Vera current past evidence evolution acute leukemia 9 . Any hematological malignancy cite thought highrisk increase chance post HSCT relapse . Patients category require specific approval PI TJU BMT attend physician group entrance . 2 . Patients must relate donor least 4 antigen match Human Leukocyte Antigen ( HLA ) A ; B ; C ; DR locus . 3 . Patients must adequate organ function : 1 . Left ventricular end diastolic function ( LVEF ) &gt; 50 % 2 . Diffusion Lung Capacity Oxygen ( DLCO ) &gt; 50 % predict correct hemoglobin 3 . Adequate liver function define serum bilirubin &lt; 1.8 , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2.5X upper limit normal 4 . Creatinine Clearance ≥ 60 mL/min 4 . Performance status ≥ 80 % ( TJU Karnofsky ) patient ≥ 60 year old ≥70 % patient &lt; 60 . 5 . Hematopoietic cell transplantcomorbidity index ( HCTCI ) Score ≤ 4 point patient ≥ 60 year old ≤ 5 point patient &lt; 60 . 6 . Patients must willing use contraception childbearing potential 7 . Able give inform consent 8 . No previous radiation history negate ability safely receive 2 Gy TBI determine radiation oncologist study coinvestigator responsible patient 1 . Performance status &lt; 80 % ( TJU Karnofsky ) patient ≥ 60 year old &lt; 70 % patient &lt; 60 . 2 . HCTCI Score &gt; 4 point patient ≥ 60 year old &gt; 5 point patient &lt; 60 . 3 . HIV positive 4 . Active involvement central nervous system malignancy 5 . Inability obtain informed consent 6 . Pregnancy 7 . Patients life expectancy &lt; 6 month reason underlie hematologic/oncologic disorder 8 . Patients receive alemtuzumab within 8 week transplant admission , recently receive horse rabbit antthymocyte globulin ATG level &gt; 2 ugm/ml 9 . Patients evidence another malignancy , exclusive skin cancer require local treatment , enrol protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>